Tag: MCL


Immunotherapy Web Featured Images 91

Anti-CD19 CAR-T cells therapy (Tecartus) has been autorized for use in mantle ce...

Tecartus is a cancer medicine used to treat adults with mantle cell lymphoma. It is used when the cancer has come back after two or more previous treatments including a type of cancer medicine called a Bruton’s tyrosine kinase (BTK) inhibitor. Mantle cell lymphoma is rare, and Tecartus was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 13 November 2019. The active substance in Tecartus consists of genetically modified white blood cells (called autologous anti-CD19-transduced CD3+ cells).

Visit website
Immunotherapy Web Featured Images 5

Tecartus Recommended for EU Approval as CAR T-cell Therapy for Mantle Cell Lymph...

A committee of the European Medicines Agency (EMA) has recommended the conditional approval of Tecartus (brexucabtagene autoleucel) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL).

Visit website